Ray D E, Cavanagh J B, Nolan C C, Williams S C
MRC Toxicology Unit, University of Leicester, Institute of Psychiatry, London, United Kingdom.
AJNR Am J Neuroradiol. 1996 Feb;17(2):365-73.
To determine the neurotoxic potential of gadopentetate dimeglumine in an animal model that allowed the agent to avoid the blood-brain barrier. Gadopentetate dimeglumine is known to produce functional changes when injected into the cerebrospinal fluid, and we hypothesized that such changes might be associated with morphologic damage.
Conscious rats, surgically prepared with a lateral ventricular cannula, were given a slow injection of gadopentetate dimeglumine into the lateral ventricle, and behavioral and neuropathologic changes were noted.
Gadopentetate dimeglumine produced signs of acute neurotoxicity over several hours (stereotyped movements and myoclonus), medium-term signs over several days (ataxia and tremor), and neuropathologic changes over 24 hours, with reactive changes persisting for 42 days. All of the above were dose-dependent over the range of 2.5 to 15 mumol/g brain. The lowest dose producing morphologic or behavioral changes was 5 mu mol/g brain. Iso-osmotic, isovolumetric injections of sucrose produced no such effects. Focal lesions occurred within the thalamus, brain stem, and spinal cord, with necrosis of glia, loss of myelin, and, usually, sparing of neurons and nerve fibers. Persisting ataxia was always associated with brain stem or spinal cord lesions.
Intraventricular administration of contrast medium allows toxicity to be evaluated in areas such as the spinal cord that are not accessible by osmotic opening. While it is unlikely that these toxic effects would be seen at the doses used for clinical imaging by the intravenous route, gadopentetate dimeglumine clearly has some neurotoxic and neuropathologic potential. Although the acute excitation could be attributed to a transiently high local concentration of the agent at the injection site, the lesions were widely distributed through the brain and spinal cord and may reflect a region-specific neurotoxic action, possibly related to central pontine myelinolysis.
在一种能使造影剂避开血脑屏障的动物模型中,确定钆喷酸葡胺的神经毒性潜力。已知将钆喷酸葡胺注入脑脊液时会产生功能变化,我们推测这种变化可能与形态学损伤有关。
给通过外科手术植入侧脑室插管的清醒大鼠缓慢注入钆喷酸葡胺到侧脑室,并记录行为和神经病理学变化。
钆喷酸葡胺在数小时内产生急性神经毒性体征(刻板运动和肌阵挛),数天内产生中期体征(共济失调和震颤),24小时内出现神经病理学变化,反应性变化持续42天。在2.5至15 μmol/g脑的剂量范围内,上述所有情况均呈剂量依赖性。产生形态学或行为变化的最低剂量为5 μmol/g脑。等渗、等容注射蔗糖未产生此类影响。局灶性病变发生在丘脑、脑干和脊髓内,伴有胶质细胞坏死、髓鞘脱失,且通常神经元和神经纤维未受影响。持续的共济失调总是与脑干或脊髓病变相关。
脑室内给予造影剂可在诸如脊髓等无法通过渗透性开放进入的区域评估毒性。虽然在静脉途径用于临床成像的剂量下不太可能出现这些毒性作用,但钆喷酸葡胺显然具有一定的神经毒性和神经病理学潜力。尽管急性兴奋可能归因于注射部位药物的局部浓度短暂升高,但病变广泛分布于脑和脊髓,可能反映了一种区域特异性神经毒性作用,可能与中枢性桥脑髓鞘溶解有关。